<DOC>
	<DOCNO>NCT02137915</DOCNO>
	<brief_summary>This study do determine long-term safety possible benefit transplant Human Central Nervous System Stem Cells ( HuCNS-SC ) patient Geographic Atrophy Age-Related Macular Degeneration . This long-term follow-up study limited individual receive transplant HuCNS-SC cell one eye part CL-N01-AMD study . No additional study product give 4-year long-term follow-up study .</brief_summary>
	<brief_title>Long-Term Follow-up Safety Study Human Central Nervous System Stem Cells Subjects With Geographic Atrophy Age-Related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<criteria>Must complete Study CLN01AMD Must able provide write informed consent prior study related procedure Agree comply good faith condition study attend require study visit Inability comply study procedure visit Since enrol Study CLN01AMD , enter , enter another investigational study , opinion Principal Investigator ( PI ) , might confound study interpretation . Received offstudy immunosuppressive agent leadin study receive immunosuppressive agent since complete leadin study</criteria>
	<gender>All</gender>
	<minimum_age>51 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>AMD</keyword>
</DOC>